Drug profile · INN
ado-trastuzumab emtansine
KADCYLA
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
ado-trastuzumab emtansine (KADCYLA) is an FDA-listed pharmaceutical active ingredient. Route of administration: single-use. Current US regulatory status: approved.
Key facts
INN ado-trastuzumab emtansine
Brand KADCYLA
Route SINGLE-USE
Formulation VIAL
Frequently asked questions
What is ado-trastuzumab emtansine?
ado-trastuzumab emtansine (KADCYLA) is an FDA-listed pharmaceutical active ingredient. Route of administration: single-use. Current US regulatory status: approved.
What is the brand name for ado-trastuzumab emtansine?
KADCYLA is a marketed brand name for ado-trastuzumab emtansine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ado-trastuzumab emtansine?
ado-trastuzumab emtansine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.